Skip to content

The USGI Medical ESSENTIAL Study for Weight Loss

A RANDOMIZED, SUBJECT AND EVALUATOR-BLINDED, PARALLEL-GROUP, MULTICENTER CLINICAL TRIAL USING AN ENDOSCOPIC SUTURING DEVICE (G-CATH EZ™ SUTURE ANCHOR DELIVERY CATHETER) FOR PRIMARY WEIGHT LOSS

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01958385
Enrollment
377
Registered
2013-10-09
Start date
2013-12-01
Completion date
2016-08-01
Last updated
2017-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Total Body Weight Loss

Brief summary

This is a multicenter, randomized, evaluator and subject blinded, parallel-group, controlled study intended to evaluate the safety and efficacy of treating obese patients with the placement of g-Cath EZ suture anchors followed by a structured diet and exercise plan as compared to a sham procedure followed by the same diet and exercise plan. Subjects will be randomly assigned in a 2:1 ratio to the treatment procedure followed by diet and exercise or the sham procedure followed by diet and exercise. After un-blinding at 12 months post-treatment, sham patients can choose to have the treatment procedure as well.

Interventions

DEVICEplacement of g-Cath EZ suture anchors
PROCEDURESham procedure
BEHAVIORALDiet and Exercise

A structured diet and exercise plan

Sponsors

USGI Medical
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
22 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Provide written informed consent. 2. Be male or female subjects between the ages of 22-60 years. 3. If female, be either post-menopausal, surgically sterile or agree to practice birth control during year of study and have negative serum HCG at screening and baseline. 4. Have a Body Mass Index (BMI) of ≥30 and \<35 with at least one non-severe co-morbid obesity related condition or a BMI ≥ 35 and \< 40 with or without a non-severe obesity related co-morbid condition, where a severe co-morbid condition is defined as severe if symptoms cause severe discomfort, performance of daily activities is compromised, and/or condition is not entirely controlled with prescription drug therapy. 5. Have had no significant weight change (+/- 5% of total body weight) in last 6 months. 6. Have an American Society Anesthesiologists-PS score ≤ 2 (Appendix III). 7. Agrees not to have any additional weight loss interventional procedures, liposuction, or take any over the counter or prescription weight loss medication for 24 months following study enrollment. 8. Have not taken any prescription or over the counter weight loss medications for at least 6 months and agrees not to utilize for 12 months following study enrollment. 9. Be willing to cooperate with post-operative dietary recommendations and assessment tests. 10. Reside within a reasonable distance from the Investigator's treating office (\ 50 miles) and able and willing to travel to the Investigator's office to complete all routine follow-up visits.

Exclusion criteria

1. History of (or intra-operative evidence of) prior bariatric, gastric or esophageal surgery. 2. Esophageal stricture or other anatomy and/or condition that could preclude passage of endolumenal instruments. 3. Severe gastro-esophageal reflux disease (GERD), defined as symptoms that cause subject severe discomfort, compromise performance of daily activities, and/or condition is not entirely controlled with prescription drug therapy. 4. Large hiatal hernia (\>3 cm) by history or as determined by pre-randomization endoscopy. 5. Pancreatic insufficiency/disease. 6. Active gastric erosions or gastric/duodenal ulcer. 7. History of gastroparesis or symptoms that would be suggestive of gastroparesis. 8. Pregnancy or plans of pregnancy in the next 12 months. 9. Immunosuppressive medications or systemic steroids (i.e., oral prednisone) within 1 month of Visit 1. Intranasal/inhaled steroids are acceptable. 10. History of inflammatory disease of the GI tract; coagulation disorders; hepatic insufficiency or cirrhosis 11. History or present use of insulin or insulin derivatives for treatment of diabetes 12. Type II Diabetes Mellitus (as defined by HgbA1c \>6.5%) for greater than 10 years at the time of enrollment 13. Quit smoking within the last 6 months at time of enrollment or plans to quit smoking in the year after enrollment 14. Portal hypertension and/or varices. 15. Gastric outlet obstruction or stenosis. 16. Significant abnormality identified during Visit 2 (randomization visit) with endoscopy revealing large hiatal hernia, gastric ulcer, gastric erosions, etc. 17. Patient has a history of drug or alcohol abuse or positive at screening for drugs of abuse. 18. Beck Depression Inventory (Short) Score ≥12 and/or uncontrolled depression after pre-enrollment psychological and medical assessment. 19. Present or past history of psychosis, bipolar disease, or obsessive compulsive disorder after pre-enrollment history and medical /psychological assessment. 20. Non-ambulatory or has significant impairment of mobility. 21. Known hormonal or genetic cause for obesity with the exception of treated hypothyroidism. 22. Participating in another clinical study. 23. Is a relative of investigator or his/her staff, or is employed by investigator or institution involved in the study. 24. Subjects with a personal history of allergic/anaphylactic reactions including hypersensitivity to the drugs or materials that will be utilized in the study procedure.

Design outcomes

Primary

MeasureTime frameDescription
Total Body Weight LossEnrollment to 12 monthsEvaluate the effectiveness of the g-Cath EZ™ Suture Anchor Delivery Catheter (USGI Medical, San Clemente, CA, USA) with diet and exercise as an early weight loss intervention for Class I obesity subjects with at least one non-severe obesity related co-morbid condition or Class II obesity subjects with or without a non-severe obesity related co-morbid condition compared to a sham procedure, diet and exercise group.

Secondary

MeasureTime frameDescription
Quality of Life scores (IWQOL)enrollment to 12 monthsAssessment of changes
Comorbid statusEnrollment to 12 monthsAssessment of changes from baseline at 12 months in hypertension, diabetes, and hyperlipidemia
Eating Behavior changesEnrollment to 12 monthsassessment of changes from baseline at 12 months in eating behavior scores (TFEQ) and subjective changes in food capacity, hunger, and satiety in both study groups

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026